AR053811A1 - USE OF A SODIUM CHANNEL BLOCKER AND ITS ANALOGS FOR THE TREATMENT OF NICOTINE DEPENDENCE - Google Patents

USE OF A SODIUM CHANNEL BLOCKER AND ITS ANALOGS FOR THE TREATMENT OF NICOTINE DEPENDENCE

Info

Publication number
AR053811A1
AR053811A1 ARP060100483A ARP060100483A AR053811A1 AR 053811 A1 AR053811 A1 AR 053811A1 AR P060100483 A ARP060100483 A AR P060100483A AR P060100483 A ARP060100483 A AR P060100483A AR 053811 A1 AR053811 A1 AR 053811A1
Authority
AR
Argentina
Prior art keywords
treatment
sodium channel
channel blocker
analogs
nicotine dependence
Prior art date
Application number
ARP060100483A
Other languages
Spanish (es)
Inventor
Helmut Heinrich Buschmann
Gomis Antonio Farre
Hernandez Jose Miguel Vela
Original Assignee
Esteve Labor Dr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP05384001A external-priority patent/EP1690541A1/en
Priority claimed from EP05384002A external-priority patent/EP1714655A1/en
Application filed by Esteve Labor Dr filed Critical Esteve Labor Dr
Publication of AR053811A1 publication Critical patent/AR053811A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Uso de un bloqueador del canal de sodio tal como la tetrodotoxina o saxitoxina, sus análogos y derivados, sus sales farmacéuticamente aceptables así como su posible combinacion con nicotina en productos medicinales para terapia humana y/o animal para el tratamiento de la dependencia de la nicotina.Use of a sodium channel blocker such as tetrodotoxin or saxitoxin, its analogues and derivatives, its pharmaceutically acceptable salts as well as its possible combination with nicotine in medicinal products for human and / or animal therapy for the treatment of nicotine dependence .

ARP060100483A 2005-02-11 2006-02-10 USE OF A SODIUM CHANNEL BLOCKER AND ITS ANALOGS FOR THE TREATMENT OF NICOTINE DEPENDENCE AR053811A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05384001A EP1690541A1 (en) 2005-02-11 2005-02-11 Use of a sodium channel blocker and their analogues for the treatment of nicotine dependency
EP05384002A EP1714655A1 (en) 2005-04-22 2005-04-22 Use of sodium channel blockers and their analogues for the treatment of nicotine dependency

Publications (1)

Publication Number Publication Date
AR053811A1 true AR053811A1 (en) 2007-05-23

Family

ID=36636342

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060100483A AR053811A1 (en) 2005-02-11 2006-02-10 USE OF A SODIUM CHANNEL BLOCKER AND ITS ANALOGS FOR THE TREATMENT OF NICOTINE DEPENDENCE

Country Status (6)

Country Link
EP (1) EP1853268A1 (en)
AR (1) AR053811A1 (en)
CA (1) CA2597101A1 (en)
PE (1) PE20061036A1 (en)
TW (1) TW200640463A (en)
WO (1) WO2006084765A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201602576D0 (en) * 2016-02-12 2016-03-30 Bergen Teknologioverforing As Process

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09510221A (en) * 1994-03-17 1997-10-14 ナンニン メープル リーフ ファーマスーティカル カンパニー リミテッド Use of aminohydrogenated quinazoline compounds and their derivatives for withdrawal from drug dependence
CN1284536C (en) * 2000-09-18 2006-11-15 威克斯医药有限公司 Antalgic method by general medicine application

Also Published As

Publication number Publication date
PE20061036A1 (en) 2006-11-24
CA2597101A1 (en) 2006-08-17
WO2006084765A1 (en) 2006-08-17
EP1853268A1 (en) 2007-11-14
TW200640463A (en) 2006-12-01

Similar Documents

Publication Publication Date Title
CY1124135T1 (en) DOSAGE FORMS FOR THE TREATMENT OF ROMRE'S DISEASE
MX2020008616A (en) Sublingual fentanyl spray.
CY1113766T1 (en) INDOLIDONES PRODUCTS FOR THE TREATMENT OR PREVENTION OF DISEASES
AR059390A1 (en) USE OF FLIBANSERINE FOR THE TREATMENT OF PREMENOPAUSIC SEXUAL DESIRE DISORDERS
UY29633A1 (en) OXINDOL DERIVATIVES
AR057946A1 (en) FORMULATION OF SUSTAINED RELEASE ZONISAMIDE
ECSP088973A (en) IMIDAZOL PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF DISEASES RELATED TO THE SYNTHETIC KINASE GLYCOGEN (GSK3)
UY35624A (en) USE OF HIGH DOSE PRIDOPIDINE TO TREAT HUNTINGTON'S DISEASE
DOP2011000264A (en) AMINOTETRALINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR USES IN THERAPY
CR8102A (en) DERIVATIVES OF PIRAZOLO-QUINAZOLINA, PROCEDURE FOR PREPARATION AND ITS USE AS QUINASE INHIBITORS
CL2011000170A1 (en) Solid and stabilized pharmaceutical composition comprising a pharmaceutically active ingredient, titanium oxide and a plasticizer; procedure to stabilize the pharmaceutical composition during a light irradiation.
GT200500378A (en) MACROLIDOS
AR062402A1 (en) USE OF COMPOUNDS AND DERIVATIVES OF 2,5-DIHYDROXIBENZENE FOR THE TREATMENT OF SKIN CANCER
NO20082097L (en) Pharmaceutical compositions
CY1114163T1 (en) METHODS OF USE OF ANGIOPYCIN COMPETITORS WITH CARBON CYCLOTHERIC AGENTS TO REDUCE CARDIOTOXICITY AND / OR IMPROVEMENT
BRPI0311189B8 (en) pharmaceutical compositions containing flibanserin polymorph a, as well as its use
PE20181332A1 (en) METHODS OF SEDATION AND PARENTERAL FORMULATION FOR USE DURING THE TREATMENT OF CRITICAL CARE
NO20024646L (en) Combination therapies with vasculature-damaging activity
CL2012001671A1 (en) Compounds derived from (methylsulfonyl) -ethyl-benzenoisoindoline; pharmaceutical composition that comprises them, use in the treatment of cancer, pain, CNS disorders, dermatological diseases, among others.
ECSP10010553A (en) USE OF DRONEDARONE OR A PHARMACEUTICALLY ACCEPTABLE SALT OF THIS, FOR THE PREPARATION OF A MEDICINAL PRODUCT TO REGULATE THE LEVEL OF POTASSIUM IN THE BLOOD
AR048672A1 (en) DISINTEGRATION TABLETS THAT INCLUDE LICARBAZEPINA
CL2020000471A1 (en) Treatment regimens.
AR053811A1 (en) USE OF A SODIUM CHANNEL BLOCKER AND ITS ANALOGS FOR THE TREATMENT OF NICOTINE DEPENDENCE
CY1111805T1 (en) Substituted Cylinders III
DK1220676T3 (en) Prevention of colorectal cancer

Legal Events

Date Code Title Description
FA Abandonment or withdrawal